News | November 03, 2023
Dr Lal Path Labs posts Q2 FY24 consolidated PAT at Rs. 109.3 Cr
Dr. Lal Path Labs has reported total income of Rs. 619.4 crores during the period ended September 30, 2023
Dr. Lal Path Labs has reported total income of Rs. 619.4 crores during the period ended September 30, 2023
The company has posted net profit of Rs.115.08 crores for half year ended September 30, 202
Sun Pharmaceutical Industries has reported total income of Rs. 12486.02 crores during the period ended September 30, 2023
Mankind Pharma has reported total income of Rs. 2768.07 crores during the period ended September 30, 2023
Thyrocare Technologies has reported total income of Rs. 150.17 crores during the period ended September 30, 2023
Ajanta Pharma has reported total income of Rs. 1049.77 crores during the period ended September 30, 2023
The inspection of the facility conducted from August 7 to August 11, 2023
Revenue in the three months ended on Oct. 1 also slipped by 42% to US$ 13.23 billion
India is following a holistic and inclusive approach in alignment with the vison of Universal Health Coverage and the resolute commitment to ‘leave no one behind
The drug will be marketed by Sun Pharma under the brand name RYTSTAT
Subscribe To Our Newsletter & Stay Updated
